Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOHEP vs CALCIUM GLUCEPTATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism (FDA-approved),Prophylaxis of venous thromboembolism in patients undergoing hip replacement surgery,Prophylaxis of venous thromboembolism in patients undergoing knee replacement surgery,Prophylaxis of venous thromboembolism in abdominal surgery
Treatment of hypocalcemia,Calcium supplementation in patients requiring parenteral calcium,Treatment of hypermagnesemia,Cardiac resuscitation (as an adjunct),Treatment of calcium channel blocker overdose
Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Tinzaparin is primarily metabolized in the liver via desulfation and depolymerization, with some involvement of renal excretion of lower molecular weight fragments.
Calcium gluceptate is not metabolized; it dissociates into calcium ions and gluceptate. Calcium ions are excreted primarily in feces and urine, with renal handling involving reabsorption and secretion.
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
90% bound to antithrombin III.
~45% bound to albumin.
0.15-0.25 L/kg; reflects limited extravascular distribution consistent with high protein binding.
0.15-0.25 L/kg; represents distribution mainly in extracellular fluid.
Subcutaneous: 90-100%.
IV: 100%; IM: not well characterized; oral: negligible (absorbed poorly, systemic bioavailability <1% as calcium gluceptate dissociates in GI tract).
For Cr Cl 30-50 m L/min: dose reduction by 25%; Cr Cl <30 m L/min: dose reduction by 50% and monitor anti-Xa activity. Alternative: avoid use if Cr Cl <30 m L/min.
GFR >50: No adjustment. GFR 30-50: Reduce dose by 25%. GFR <30: Reduce dose by 50% and monitor serum calcium closely. Dialysis: Dose after hemodialysis.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: contraindicated.
No dose adjustment required for hepatic impairment. However, monitor ionized calcium in severe hepatic failure due to altered binding proteins.
Not recommended for use in children due to lack of safety and efficacy data. Consider alternative low molecular weight heparins with established pediatric dosing.
Neonates and infants: 100-200 mg elemental calcium/kg/day IV divided every 6 hours. Children: 200-500 mg elemental calcium/kg/day IV divided every 6 hours. Maximum: 1 g elemental calcium per dose.
Elderly patients (age ≥75 years) may have reduced renal function; dose should be based on renal function (see renal adjustment). Caution as increased risk of bleeding, especially with body weight <45 kg. Consider anti-Xa monitoring.
Use lower initial doses (e.g., 1-2 mg/kg elemental calcium) due to reduced renal function and increased risk of hypercalcemia. Monitor serum calcium and phosphate levels.
Epidural or spinal hematomas may occur in patients anticoagulated with low molecular weight heparins or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider monitoring for signs and symptoms of neurological impairment and urgent treatment if suspected.
No FDA black box warning.
Risk of hemorrhage: monitor for signs of bleeding,Thrombocytopenia: risk of heparin-induced thrombocytopenia (HIT),Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) as exposure may be increased,Do not administer intramuscularly due to risk of hematoma,Monitor anti-factor Xa activity in patients with severe renal impairment, obesity, or during pregnancy
Risk of hypercalcemia, especially in patients with renal impairment,Avoid rapid intravenous administration to prevent cardiac arrest,Use with caution in patients with sarcoidosis or digitalis toxicity,Monitor serum calcium levels during therapy,Extravasation may cause tissue necrosis
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT),Active major bleeding,Known hypersensitivity to tinzaparin, heparin, or pork products,Concurrent use of neuraxial anesthesia or spinal puncture (relative; requires caution),Severe uncontrolled hypertension
Hypercalcemia,Hypersensitivity to calcium gluceptate or any component,Ventricular fibrillation,Patients with known calcium-containing calculi
No specific food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if also on warfarin; not required with Innohep alone. Limit alcohol intake as it may increase bleeding risk.
Avoid high-calcium foods (dairy, fortified cereals) during acute therapy to prevent hypercalcemia. Limit vitamin D-rich foods (fatty fish, fortified milk). Do not take oral calcium within 1 hour of iron or thyroid medications. Avoid excessive caffeine and alcohol.
Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use during pregnancy only if clearly needed. First trimester: minimal risk. Second and third trimesters: increased risk of bleeding, but no structural teratogenic effects reported.
Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No increased risk of major malformations. Second and third trimesters: Adequate intake supports fetal skeletal mineralization; excess may cause hypercalcemia in the infant. No known teratogenicity.
Tinzaparin is not excreted into breast milk in significant amounts due to high molecular weight. M/P ratio not established; expected to be low. Considered compatible with breastfeeding by most authorities.
Calcium gluceptate is considered safe during breastfeeding. Calcium is naturally present in breast milk; supplementation does not significantly alter milk calcium levels. M/P ratio not established, but endogenous calcium transport suggests minimal risk. Use with caution in mothers with hypercalcemia.
Pregnancy may require dose adjustments due to increased plasma volume and renal clearance. Monitor anti-Xa levels if needed; adjust dose to maintain therapeutic range. No standard dosing algorithm; individualize based on weight and renal function.
No specific dose adjustment required in pregnancy; maintain recommended daily intake (1000-1300 mg elemental calcium). Pharmacokinetic changes in pregnancy (increased absorption, renal clearance) may slightly alter requirements, but standard doses are safe. Intravenous use should be adjusted based on serum calcium monitoring.
Use anti-Xa monitoring in patients with renal impairment (Cr Cl <30 m L/min) or extremes of body weight. Innohep (tinzaparin) has a higher molecular weight than other LMWHs, leading to a longer half-life and potential for accumulation in renal failure. Avoid in patients with heparin-induced thrombocytopenia (HIT) history. Protamine sulfate partially reverses effect (up to 60%). Monitor platelets periodically due to risk of HIT.
Calcium gluceptate is used for acute hypocalcemia, hyperkalemia cardiotoxicity, and hypermagnesemia. Administer IV slowly (0.5-1 m L/min) to avoid arrhythmias; monitor ECG during infusion. Do not mix with bicarbonate, phosphate, or sulfate-containing solutions. Extravasation causes tissue necrosis; use central line for peripheral therapy. Correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia.
Do not stop or change dose without consulting your doctor.,Report any signs of unusual bleeding or bruising, black/tarry stools, or blood in urine.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed.,Use electric razor and soft toothbrush to minimize bleeding risk.,Seek immediate medical help if you experience severe headache, vision changes, or signs of allergic reaction.,Do not rub injection site; rotate sites (abdomen, thigh, upper arm).,Keep a record of injection dates and times.
Report any burning or pain at injection site immediately.,Avoid taking calcium supplements or antacids without consulting your doctor.,Tell your doctor if you have kidney stones, parathyroid disorders, or heart disease.,Do not stop other calcium medications abruptly.,Seek emergency care for difficulty breathing or chest tightness after infusion.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOHEP vs CALCIUM GLUCEPTATE, answered by our medical review team.
INNOHEP is a Low Molecular Weight Heparin that works by Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.. CALCIUM GLUCEPTATE is a Electrolyte Supplement that works by Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOHEP and CALCIUM GLUCEPTATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOHEP is: Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.. The standard adult dose of CALCIUM GLUCEPTATE is: IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOHEP and CALCIUM GLUCEPTATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOHEP is classified as Category C. Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use . CALCIUM GLUCEPTATE is classified as Category C. Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.